DUSP22 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the dual-specificity phosphatase DUSP22 in the near-haploid HAP1 cell line. This heterogeneous pool of edited cells abolishes DUSP22 expression, providing a powerful loss-of-function model to interrogate mitogen-activated protein kinase (MAPK) signaling dynamics, tumor suppression mechanisms, and immune regulatory processes. The polyclonal format preserves population-level diversity while ensuring robust functional ablation, making it suitable for high-throughput phenotypic screens, phospho-signaling analyses, and comparative studies with isogenic wild-type controls.
Originating from a near-haploid derivative of the KBM-7 chronic myeloid leukemia cell line, HAP1 serves as a versatile host for genetic studies due to its stable karyotype and adherent, fibroblast-like morphology. The haploid genome simplifies CRISPR editing and downstream genotyping, enabling efficient disruption of target loci without confounding paralog compensation. This engineered knockout model leverages HAP1??s genetic tractability to dissect DUSP22-mediated regulatory networks in a clean cellular background, facilitating interpretation of signaling phenotypes and drug responses.
DUSP22 is a dual-specificity phosphatase that critically terminates stress-activated MAPK cascades by dephosphorylating the regulatory threonine and tyrosine residues of JNK1/2/3 and p38 MAPK. Its activity is triggered by upstream stimuli such as T cell receptor activation, oxidative stress, and reactive oxygen species. In the knockout setting, sustained phosphorylation of JNK and p38 leads to persistent activation of downstream effectors including c-Jun, ATF2, and STAT3, biasing transcriptional programs toward proliferation, survival, or apoptosis depending on cellular context. DUSP22 also interacts with scaffold proteins like JIP1 and, in pathological lymphoid rearrangements, forms an oncogenic fusion with IRF4, underscoring its relevance in lymphoma biology.
Embedding DUSP22 knockout in HAP1 cells generates an experimentally streamlined model for studying stress kinase pathways and their pathological dysregulation. The near-haploid background eliminates allele-specific artifacts, while the leukemic origin offers a context for evaluating tumor suppressor functions and therapeutic vulnerabilities. Constitutive JNK/p38 hyperactivation in these cells models core signaling features of peripheral T-cell lymphomas harboring DUSP22 alterations, enabling mechanistic dissection of transformation and testing of pathway-targeted inhibitors such as JNK or p38 antagonists.
Typical applications include quantitative Western blotting for phospho-JNK and phospho-p38, RT-qPCR profiling of immediate downstream transcripts (c-Jun, ATF2), transcriptome-wide RNA-seq to map global expression changes, and phospho-kinase arrays for off-target pathway assessment. The model is amenable to viability and apoptosis assays under stress conditions, as well as drug sensitivity screenings against JNK/p38 pathway inhibitors. It supports functional genomics, CRISPR-based modifier screens, and validation studies in immune-cell signaling and lymphoma research. For additional information, please contact Ascent Research.
